|
Dr. Gilman joined the Company in March, 2004 and currently leads the ActivBiotics management team as Chairman and CEO. Dr. Gilman came to ActivBiotics from Millennium Pharmaceuticals where he held a number of senior leadership roles including Vice President and General Manager, Inflammation, responsible for all aspects of the Inflammation business from early gene discovery to product commercialization. Prior to Millennium, he was Group Director at Pfizer Global Research and Development where he was responsible for drug discovery of novel antibacterial agents as well as several other therapeutic areas. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. He currently serves on the board of the Massachusetts Biotechnology Association and Nextcea, Inc., an early-stage private company, and has previously served on the Boards of the Inflammation Research Association, Arthritis Foundation (Philadelphia) and the Biotechnology Advisory Board at Worcester Polytechnical Institute. Dr. Gilman received his PhD and MS degrees in microbiology/immunology from Pennsylvania State University and his post-doctoral training at Scripps Clinic and Research Foundation. He has authored over 120 scientific publications, abstracts and book chapters and is an inventor on several issued US and international patents | 